Abstract
Background:A phase 3, randomized, double-blind, placebo-controlled, withdrawal, global efficacy, and safety trial was conducted in 20 countries (NCT03773978). The trial consisted of a 2-week safety and pharmacokinetic period, a 12-week...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
